



(51) International Patent Classification:

A61K 31/4184 (2006.01) A61K 39/395 (2006.01)
A61K 31/506 (2006.01) A61K 45/06 (2006.01)
A61K 31/517 (2006.01) A61P 35/00 (2006.01)
A61K 31/565 (2006.01)

(21) International Application Number:

PCT/US2023/078155

(22) International Filing Date:

30 October 2023 (30.10.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/421,082	31 October 2022 (31.10.2022)	US
63/423,383	07 November 2022 (07.11.2022)	US
63/488,674	06 March 2023 (06.03.2023)	US
63/531,990	10 August 2023 (10.08.2023)	US

(71) Applicant: **SCORPION THERAPEUTICS, INC.**
[US/US]; One Winthrop Square, Suite 400, Boston, MA 02110 (US).

(72) Inventors: **ST. JEAN, JR., David**; One Winthrop Square, Suite 400, Boston, MA 02110 (US). **STUART, Darrin**; One Winthrop Square, Suite 400, Boston, MA 02110 (US). **BUCKBINDER, Leonard**; One Winthrop Square, Suite


400, Boston, MA 02110 (US). **JACKSON, Erica**; One Winthrop Square, Suite 400, Boston, MA 02110 (US). **TIEU, Trang, Nguyet**; One Winthrop Square, Suite 400, Boston, MA 02110 (US). **LADD, Brendon**; One Winthrop Square, Suite 400, Boston, MA 02110 (US). **ALLTUCK-ER, Jacob, Tyler**; One Winthrop Square, Suite 400, Boston, MA 02110 (US).

(74) Agent: **BATES, Caleb A.** et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, MN 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: COMBINATION THERAPY FOR TREATING CANCER



(57) Abstract: This disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3K α) for use in combination with additional therapeutic agents for treating a condition, disease or disorder in which increased (e.g., excessive) PI3K α activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject.

[Continued on next page]

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*